BCAL Diagnostics LimitedASX: BDX

Quarterly Activities/Appendix 4C Cash Flow Report

· Issued by BCAL Diagnostics Limited via ASX

Filed with ASX ·

ASX Announcement 30 October 2026 Appendix 4C – September 2026 Quarterly Activities Report Highlights • Clinical validation completed for BREASTESTplus™ 2 in women aged 30 years+ across all breast densities; launch targeted for November 2026 and accreditation and operational activities...

View Attachment

6ix is reading this filing.

BCAL Diagnostics Limited on 6ix

Earlier from BCAL Diagnostics

All BCAL Diagnostics news releases